Drug intelligence / Profile preview

Al18F-NOTA-grazytracer + 68Ga-grazytracer

Development stage
Phase 1
Lead developer
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Modality
Small Molecules, Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics
Administration
Intravenous
01

Overview

Al18F-NOTA-grazytracer and 68Ga-grazytracer are investigational PET imaging radiopharmaceuticals designed to target granzyme B, a serine protease released by activated cytotoxic T cells and natural killer cells. Developed by the Cancer Institute and Hospital, Chinese Academy of Medical Sciences, these tracers serve as non-invasive biomarkers for the tumor immune microenvironment. By binding to granzyme B, they allow for the visualization of cytotoxic T-cell activity within tumors, which can help predict treatment response and prognosis in patients with aggressive lymphoma and those undergoing immunotherapy. The two versions utilize different radioisotopes (Fluorine-18 via an AlF-NOTA complex and Gallium-68) to facilitate PET/CT imaging.

Other names
Al18F-NOTA-grazytracer/68Ga-grazytracer
02

Targets

GZMB (Granzyme B)

Beyond the preview

Go deeper on Al18F-NOTA-grazytracer + 68Ga-grazytracer.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Al18F-NOTA-grazytracer + 68Ga-grazytracer.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call